Immuno-Oncology Journal Club/Trainee Presentations

Fridays at 1:30 pm EST. Via Zoom  

May 19, 2023

LncRNA XIST from the bone marrow mesenchymal stem cell derived exosome promotes osteosarcoma growth and metastasis through miR-655/ACLY signal, published in Cancer Cell International. October 2022. Presented by Danielle Taray-Matheson

May 12, 2023 

Imaging glial activation using [18F]-FEPPA PET post-cranial irradiation (PhD project) presented by Sawyer Badiuk

May 5, 2023

The Effect of Akkermansia muciniphila and Its Outer Membrane Vesicles on MicroRNAs Expression of Inflammatory and Anti‑inflammatory Pathways in Human Dendritic Cells, published in Probiotics and Antimicrobial Proteins. March 2023. Presented by Amanda Liddy.

April 28, 2023

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumorCD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor, published in Immunity. January 2023. Presented by Megan Hong.

April 21, 2023

Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particlesSimultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles, published in Molecular Therapy. March 2023. Presented by Raphael Sanchez-Pupo.

March 3, 2023

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance, published in Cancer Cell. January 2023. Presented by Yeganeh Yousefi.

February 24, 2023

Diet Alters Entero-Mammary Signaling to Regulate the Breast Microbiome and Tumorigenesis, published in Cancer Res. June 2021. Presented by Hasti Gholami. 

Feburary 10, 2023

Emerging Biomedical Applications Based on the Response of Magnetic Nanoparticles to Time-Varying Magnetic Fields, published in Annual Review of Chemical and Biomolecular Engineering. April 2021. Presented by Julia Gevaert.

February 3, 2023

Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based vaccine by downregulation of PD-L1 expression, published in Cancer Immunology, Immunotherapy. January 2022. Presented by Danielle Taray-Matheson. 

January 27, 2023

Akkermansia supplementation reverses the tumorpromoting effect of the fecal microbiota transplantation in ovarian cancer, published in Cell Report. December 2022. Presented by Amandy Liddy.

December 16, 2022

Non-Invasive imagine of extracellular vesicle. Quo vaditis in vivo, published in ISEV, June 2022. Presented by Oliva Sehl.

December 9, 2022

Non-invasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy, published in J Clin Invest. July 2022. Presented by Rafael Sanchez Pupo.

December 2, 2022

Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Published in Cancer Cell, March 2022. Presented by Megan Hong. 


November 18, 2022

IL-27 improves adoptive CD89+ T cells' antitumor activity via enchancing cell survival and memory T cell differentiation. Published in Cancer Science-Wiley, November 2021. Presented by Lara Gerhardt

May 27, 2022

Tracking adoptive T cell immunotherapy using magnetic particle imaging. Published in Nanotheranostics, Vol. 5. Presented by Julia Gevaert.

May 13, 2022

Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity. Published in Immunity, December 2021. Presented by Lara Gerhardt. 

April 29, 2022

Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Published in Immunity, February 2022. Presented by Marwa Said

April 22, 2022

Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Published in Nature Communications, March 2022. Presented by Megan Hong

April 8, 2022 

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Published in Science, August 2020. Presented by Yeganeh Yousefi

March 11, 2022

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. Published in N.Eng.J of Med, June 2022. Presented by Jasna Deluce

March 4, 2022

Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Published in Nature, January 2021. Presented by Rafael E. Sánchez Pupo. 

February 25, 2022

CD39 + HBVs-CAR T and personalized tumor reactive CD8+ T cells exhibit potent anti-HCC activity. Published in Molecular Therapy, May 2022. Presented by Lara Gerhardt. 

February 18, 2022

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade. Published International Journal of Radiation Oncology, June 2021. Presented by Sawyer Badiuk.

February 11, 2022 

In vivo imaging of nanoparticle-labeled CAR T cells. Published in PNAS, January, 2022

December 4, 2021

Lack of CD8+ T cell effector differentiation duringpriming mediates checkpoint blockade resistance in non–small cell lung cancer. Published in Science Immunology. Presented by Lara Gerhardt. 

November 26, 2021

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Published in Science Translational Medicine. Presented by Melissa Evans. 

November 19, 2021

Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Published in Immunotherapy. Presented by Jasna Deluce. 

November 12, 2021

An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Published in Cancer Research. Presented by Olivia Sehl. 

October 29, 2021

Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. Published in The Journal of Clinical Investigation". Presented by Sawyer Badiuk.

October 22, 2021 

18F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy. Published in Nuclear Medicine. Presented by Rafael E. Sanchez Pupo.

October 1, 2021

An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Published in Nature, September 2021. Presented by Lara Gerhardt. 

September 24, 2021

Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against sold tumors. Published in Science Translational Medicine, August 2021. Presented by Megan Hong.

June 25, 2021 

Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. Published in International Journal of Molecular Science, May 2021. Presented by Sawyer Badiuk. 


May 28, 2021

LIMIT is an immunogenic IncRNA in cancer immunity and immunotherapy.Published in Nature, May 2021. Presented by Yili Xu.

May 14, 2021

Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer. Published in Journal for ImmunoTherapy of Cancer, 2021. Presented by Megan Hong. 

May 7, 2021

Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells by Nathan Singh et al. published in Nature Medicine, 2021. Presented by Hita Rishi.

April 23, 2021

Sequence of aPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses.” by Wei et al. and was published in Science Immunology. Presented by Lara Gerdhart. Supplementary Material 

April 9, 2021

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, 2019, presented by Dr. Jasna Deluce. 

March 26, 2021

Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer, The Journal of Nuclear Medicine, February 2021, presented by Dr. Ting-Yim Lee. 

March 19, 2021

Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy. Nature Communication, March 2021, presented by Lara Gerhardt.

March 12, 2021

Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer, PNAS, November 2019, presented by Yili Xiu.

March 5, 2021

FMT + IO Trials.  Dr. Mithunah Krishnamoorthy to present two recently published papers in Science, February 2021

February 26, 2021

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Science Direct, August 2018 presented by Melissa Evans.

February 19, 2021

Chitosan/ÿ-PGA nanoparticles-based immunotherapy as adjuvant to radiotherapy in breast cancer. PubMed, October 2020 presented by Sawyer Badiuk

February 12, 2021

Cancelled due to the IO symposium

February 5, 2021

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018 presented by Dr. Jasna Deluce.

January 29, 2021

Personal neogantigen vaccines induce persistent memory T cell responses and epitope spreading in patients and melanoma. Nature Medicine, 2021 presented by Dr. Mithunah Krishnamoorthy.

January 22, 2021

SHP2 blockade enhances anti-tumor immunity via tumor cell-intrinsic and extrinsic mechanisms, Scientific Reports volume 11, Article number: 1399 (2021) presented by Yili Xu

January 15, 2021

Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade, Cell Death & Disease volume 11, Article number: 1062 (2020) presented by Hita Rishi

December 11, 2020

Imaging of T-cells and their responses during anti-cancer immunotherapy, Theranostics 2019, Vol. 9, Issue 25 presented by Dr. Ting Lee

December 4, 2020

MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects, Nature Immunology, presented by Dr. Mithunah Krishnamoorthy

November 27, 2020

Enhanced CAR-T activity against established tumors by polarizing human T cells to secreteinterleukin-9, Nature Communications, (2020) 11:5902 Presented by Yili Xu

November 13, 2020

Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer, Nature,, presented by Mikal El-Hajjar

November 6, 2020

Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway, OncoImmunology, 9:1, 1824643, DOI: 10.1080/2162402X.2020.1824643, presented by Lara Gerhardt